FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.

Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of ...

Explore the crucial differences between battery swapping and rapid charging for electric vehicles (EVs), examining their ...

Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Princeton, New Jersey Thursday, February 19, 2026, 11:00 Hrs [IST] ...

Starting biologic therapy at diagnosis, rather than escalating later, may significantly reduce complications and ...

This technical deep dive documents the intricate wiring and assembly of a high-performance battery system for an electric ...

Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase. | Sanofi has kicked off its preparations for the 2026 World ...

Lithium batteries power an expanding range of technologies, from electric vehicles and commercial transportation fleets to stationary energy storage systems and grid-scale backup power installations.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.20327 EPS, expectations ...

The South African digital health and telemedicine market was already valued at around R15.7 billion back in 2023, according to industry research, and is projected to grow substantially through this ...